A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)

Is this Study for You?

Let's Get Started!

Details
Age

Child

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Principal Investigator
Photograph of Amy Keating,  MD

Amy Keating, MD

Study ID

Protocol Number: 20-2471

More information available at ClinicalTrials.gov: NCT04557735

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers